Investment

ZXBio invests in the US and Chinese secondary stock market, asset-backed securities, and patents which are synergistic to ZXBio's long-term strategic plans. ZXBio performs in-house patent valuation and invests exclusively in the Healthcare Industry. 


ZXBio pioneers Intellectual Property Securitization and actively engages in valued investment opportunities.

China Government Bonds Yield Curve

US S&P Pharmaceuticals Select Industry Index

China SSE Health Care Sector Index

Patent Valuation

Yervoy (Ipilimumab)

image39

  • Brand: Yervoy (Ipilimumab)
  • Ownership: Bristol-Myers Squibb (BMS)
  • Ingredient: Humanized Anti-CTLA4 antibody (MDX010, originated from Medarex)
  • Indication: Advanced Melanoma
  • Exclusivity(Patent) Expiration Year: 2023
  • Net Present Value (Year 2018): $2,547.49 Million ($2.55 Billion)
  • Investment Recommendation: Hold/Short

Adalimumab (Humira)

image40

  • Brand: Humira (Adalimumab)
  • Ownership: AbbVie
  • Ingredient: Anti-TNFa Human Monoclonal Antibody (Derived from Phage Display)
  • Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's disease, Ulcerative colitis, Chronic psoriasis, Hidradenitis suppurative, and Juvenile idiopathic arthritis.
  • Exclusivity(Patent) Expiration Year: June 2023 (US Market)
  • Net Present Value (Year 2018): $57,366.92 Million ($57.37 Billion)
  • Investment Recommendation: Long/Hold

Insulin Glargine (Lantus)

image41

  • Brand: Lantus (Insulin Glargine)
  • Ownership: Sanofi
  • Ingredient: Long-acting basal insulin analogue (produced using recombinant DNA Technology, E. coli )
  • Indication: Type 1 Diabetes, Type 2 Diabetes (when basal long-acting insulin is needed)
  • Exclusivity(Patent) Expiration Year: Expired on Feb, 2015 (US Patent)
  • Net Present Value (Year 2018): $7,737.85 Million ($7.74 Billion)
  • Investment Recommendation: Short


Please Contact Us if You Wish to Assess Your Patent Valuation


Copyright belongs to ZXBio

Risk Hedging Tools: Financial Derivatives

image42

  

  • Backed by our manufacturing capacity, we are constructing portfolios composed of our holding products and risk-free investment to mimic financial tools: Put/Call Options, Delta hedging strategy, Delta-Gamma Hedging strategy, etc. To be updated.